Pro-senescence Therapy in Cancer Treatment: A Survey

www.surveyx.cn

Abstract

Pro-senescence therapy is an emergent strategy in cancer treatment that aims to induce cellular senescence, thereby halting tumor proliferation. This survey examines the concept, mechanisms, and applications of pro-senescence therapy, highlighting its dual role in tumor suppression and potential promotion via the senescence-associated secretory phenotype (SASP). Key mechanisms include oncogene-induced senescence (OIS) and therapy-induced senescence (TIS), which exploit cellular aging pathways to arrest cancer cell growth. The survey reviews senescence-inducing agents, such as chemical, pharmacological, and natural compounds, emphasizing their role in modulating epigenetic and genetic pathways to enforce senescence. Challenges such as the heterogeneity of senescence responses, resistance, and adverse effects are addressed, underscoring the need for precise biomarker identification and selective targeting. Current research highlights advancements in senescence-inducing agents and the potential integration of senolytics to enhance therapeutic efficacy. Clinical applications in specific cancer types, such as hepatocellular carcinoma and melanoma, demonstrate the promise of pro-senescence therapy in overcoming resistance and improving patient outcomes. Future directions involve refining therapeutic strategies, optimizing combination therapies, and addressing the dual nature of SASP to fully harness the therapeutic potential of senescence pathways in cancer treatment.

1 Introduction

1.1 Concept of Pro-senescence Therapy

Pro-senescence therapy is an innovative cancer treatment strategy aimed at halting tumor cell proliferation by inducing senescence, effectively arresting cancer progression [1]. This approach capitalizes on cellular senescence's natural tumor-suppressive properties, characterized by irreversible cell cycle arrest. A key mechanism in this context is oncogene-induced senescence (OIS), where aberrant oncogenic signaling triggers senescence, serving as an initial barrier to malignant transformation [2].

The dual roles of cellular senescence and the senescence-associated secretory phenotype (SASP) complicate this approach [1]. While senescence can suppress tumor growth, the SASP may paradoxically foster tumorigenesis under specific conditions. Understanding the regulatory mechanisms governing senescence is essential to optimize pro-senescence therapy's application in cancer treatment [2].

Pro-senescence therapy presents a potentially less harmful alternative to traditional cancer treatments that induce apoptosis, aiming to halt cancer cell proliferation while exploring new therapeutic pathways through mechanisms such as targeting oncogenes like MYC and employing therapy-induced senescence (TIS) strategies. By deepening our understanding of the molecular pathways involved in senescence, these therapies may significantly enhance cancer treatment outcomes while reducing the severe side effects associated with conventional therapies [3, 4, 5, 6].



Figure 1: chapter structure

1.2 Significance and Potential Impact

Pro-senescence therapy represents a significant advancement in cancer treatment, utilizing the dualistic nature of cellular senescence to function as both a tumor suppressor and a potential promoter of tumor aggressiveness through the SASP. This strategy harnesses the tumor-suppressive capabilities of senescence while addressing the risks associated with SASPs that can enhance tumorigenesis. By targeting these dual aspects, the approach seeks to improve patient outcomes through better tumor management and the preservation of immune surveillance within the tumor microenvironment [7, 1].

Integrating pro-senescence strategies with existing cancer treatments offers a promising pathway to enhance therapeutic efficacy, particularly in tumors resistant to apoptosis [8]. For example, in colon cancer, the need for novel strategies to effectively induce senescence is critical for improving treatment outcomes [9]. Additionally, targeting senescent tumor cells (STCs) may reduce their contribution to collective invasion and metastasis, as seen in papillary thyroid carcinoma (PTC), thus providing new hope for treatment-resistant malignancies [10].

In specific cancers like melanoma and hepatocellular carcinoma (HCC), pro-senescence therapy can induce OIS through pathways such as LPAR1, thereby improving patient outcomes via tumor-suppressive mechanisms [1]. Furthermore, TIS has been recognized for its potential to reduce side effects, enhancing the therapeutic index of cancer treatments [5].

The broader implications of pro-senescence therapy extend beyond cancer treatment, potentially improving healthspan and lifespan. Identifying key biomarkers and developing senolytic drugs can

refine therapeutic strategies and bolster anti-tumor immunity [1]. As research advances, carefully modulating TIS and its effects on the tumor microenvironment will be vital for optimizing patient outcomes and minimizing adverse effects [11].

1.3 Structure of the Survey

This survey is structured into several key sections that systematically explore pro-senescence therapy's concepts and applications in cancer treatment. The introductory section outlines the foundational principles of pro-senescence therapy, detailing its role in halting cancer progression through tumor cell senescence. This is followed by a discussion on the significance and potential impact of this therapeutic approach, emphasizing its implications for enhancing patient outcomes and integration with existing cancer treatments.

The background and core concepts section provides an overview of essential elements, including tumor cell senescence, cellular aging, and oncogene-induced senescence, focusing on senescence-inducing agents. The subsequent section examines the mechanisms of tumor cell senescence, highlighting the biological processes involved and the dual nature of senescence in cancer progression.

The survey comprehensively reviews a range of senescence-inducing agents, detailing their specific mechanisms of action and evaluating their therapeutic effectiveness across various clinical contexts, including cancer treatment and SASP modulation [4, 7, 8]. Challenges and limitations of pro-senescence therapy are identified, including issues related to resistance, selectivity, and biomarker validation. Current research and developments are showcased, highlighting recent advancements and ongoing challenges in the field.

Finally, the survey discusses therapeutic strategies and applications, including clinical trials and cancer-specific applications of pro-senescence therapy. The concluding section reflects on the future prospects of pro-senescence therapy, underscoring the need for continued research to address existing challenges and enhance therapeutic outcomes.The following sections are organized as shown in Figure 1.

2 Background and Core Concepts

2.1 Tumor Cell Senescence

Tumor cell senescence is a pivotal mechanism in cancer therapy, characterized by stable, irreversible cell cycle arrest induced by oncogenic, replicative, and therapeutic stressors. This permanent arrest effectively inhibits cancer cell proliferation, serving as a tumor-suppressive mechanism [11]. Therapy-induced senescence notably contributes to tumor suppression by ceasing cancer cell division following therapeutic interventions.

However, senescence also exhibits a dual nature, potentially facilitating malignancy through its impact on the tumor microenvironment (TME) via the senescence-associated secretory phenotype (SASP). SASP involves the secretion of pro-inflammatory cytokines, growth factors, and proteases, which can promote the growth of adjacent tumor cells [1]. This paradoxical effect can lead to therapy resistance and cancer recurrence, highlighting the necessity of comprehending its regulatory mechanisms [1].

The complexity of senescence is further illustrated by the interplay of oncogenes like MYC and RAS, which can trigger oncogene-induced senescence (OIS), halting cancer proliferation through micro-RNA and protein regulation [12]. Tailored therapeutic approaches are required to address the heterogeneity of senescence responses across different cancer types. The development of senolytic drugs, which selectively target and eliminate senescent cells, offers a promising strategy to enhance the efficacy of senescence-based therapies [1].

2.2 Cellular Aging and Senescence

Cellular aging and senescence are intertwined processes that significantly influence cancer therapy. Senescence, traditionally seen as a tumor-suppressive mechanism, enforces permanent cell cycle arrest to prevent uncontrolled proliferation. However, the dual roles of cellular senescence (CS) and SASP can either inhibit or promote tumor growth depending on the context [1]. This duality presents

challenges in therapy, as senescence can both hinder tumorigenesis and facilitate tumor progression under specific conditions.

The heterogeneity of senescent cells across cancers complicates the identification of specific markers and the selective induction of senescence in cancer cells while sparing normal cells [5]. This variability complicates senescence's role as both a protective and potentially harmful force in cancer progression.

Autophagy regulates mesenchymal stem cell (MSC) senescence, a crucial aspect of cellular aging and regeneration [13]. Modulating autophagy in senescent cells could open new therapeutic avenues to amplify the beneficial effects of senescence while mitigating adverse impacts.

The interplay between cellular aging and senescence is underscored by DNA methylation, particularly in the TERT promoter. Hypomethylation at specific genomic sites can lead to telomerase upregulation, influencing tumorigenesis. This relationship highlights the intricate connection between aging, cellular senescence, and cancer progression, as altered DNA methylation patterns contribute to the dysregulation of essential cellular functions associated with both aging and malignancy [14, 8, 15, 4, 16].

2.3 Oncogene-Induced Senescence (OIS)

Oncogene-induced senescence (OIS) enforces a permanent state of proliferative arrest in response to oncogenic stress, serving as a barrier against tumorigenesis [17]. It is initiated by activating oncogenic lesions that trigger cellular events leading to senescence, preventing the progression of pre-malignant lesions. OIS underscores its tumor-suppressive role by inhibiting cancer cell growth.

OIS regulation involves key molecular pathways, including interactions with the tumor suppressor p53. Cyclooxygenase-2 (COX-2) can inhibit p53's pro-senescent function, disrupting the senescence process and potentially leading to neoplastic transformation [18]. Targeting these pathways could enhance cancer treatment efficacy.

OIS is linked to cellular aging, as its permanent cell cycle arrest contributes to cellular aging. The SASP fosters a pro-inflammatory environment that can paradoxically promote tumor progression despite OIS-imposed growth arrest. The dual role of cellular senescence and SASP in the tumor microenvironment necessitates understanding how these factors can both hinder and facilitate cancer progression, impacting the development of effective cancer therapies [19, 20, 1].

3 Mechanisms of Tumor Cell Senescence

The mechanisms underlying tumor cell senescence involve a complex interplay of epigenetic and genetic regulations that govern the onset and maintenance of senescence, significantly impacting tumor biology and therapeutic strategies. As illustrated in Figure 2, this figure highlights the intricate mechanisms of tumor cell senescence, emphasizing the roles of epigenetic and genetic regulation, the senescence-associated secretory phenotype (SASP), cellular stress responses, and bioenergetics. Additionally, it captures the dual nature and paradox of senescence in cancer biology. Each section of the figure outlines the key factors and regulatory pathways involved, providing valuable insights into their implications for tumor progression and therapeutic strategies. This section delves into the roles of these regulatory mechanisms to enhance our understanding of tumor cell senescence.

3.1 Epigenetic and Genetic Regulation

Tumor cell senescence is orchestrated by intricate interactions between epigenetic and genetic factors that regulate pathways leading to cellular aging and growth arrest. Epigenetic modifications, such as DNA methylation and histone alterations, play a pivotal role in modulating gene expression during senescence, affecting chromatin structure and transcriptional dynamics [12, 5]. Genetic factors, including interactions of oncogenic signals with tumor suppressors like p53 and Rb, further underscore the genetic basis of senescence induction. For instance, COX-2's inhibition of p53 function illustrates the complexity of genetic regulation in senescence [18]. The SenTraGor method enhances our understanding by enabling the detection of micro-RNAs and proteins in senescent cells [12].



Figure 2: This figure illustrates the mechanisms of tumor cell senescence, highlighting the roles of epigenetic and genetic regulation, the senescence-associated secretory phenotype (SASP), cellular stress responses and bioenergetics, and the dual nature and paradox of senescence in cancer biology. Each section outlines the key factors and regulatory pathways involved, providing insights into their implications for tumor progression and therapeutic strategies.

Senescence induction occurs via stressors such as replicative exhaustion and oxidative stress, activating molecular pathways that influence tumor behavior. DNA damage response (DDR) pathways, for example, are crucial for oncogene-induced senescence (OIS) and depend on the specific epigenetic and genetic landscape [2]. The dynamic interplay between epigenetic modifications and genetic factors affects cellular stress responses and aging, influencing tumor progression and treatment outcomes [7, 12, 21, 22, 16]. Understanding these mechanisms offers insights into potential therapeutic strategies targeting senescence pathways in cancer treatment.

3.2 Senescence-Associated Secretory Phenotype (SASP)

The senescence-associated secretory phenotype (SASP) is a hallmark of senescent cells, characterized by the secretion of cytokines, chemokines, growth factors, and proteases, impacting tumor progression and treatment outcomes in context-dependent manners [7]. The SASP composition varies with senescence-inducing stimuli, differentially affecting the tumor microenvironment (TME) and neighboring cells, either suppressing or promoting tumorigenesis.

SASP factors can enhance senescent growth arrest by fostering immune surveillance and clearance of senescent cells, serving as a tumor-suppressive mechanism. Conversely, under certain conditions, SASP can promote tumor progression by intensifying inflammation and facilitating tissue remodeling [23, 7, 1, 24]. This paradoxical nature necessitates a nuanced understanding of SASP regulation to leverage its therapeutic potential effectively.

Regulation of SASP involves complex interactions among transcription factors and chromatin remodelers. For instance, MZF1 is crucial for recruiting CHD7 to the p16 INK4A promoter, indicating a regulatory mechanism for SASP components [25]. Targeting specific regulators could modulate SASP and influence tumor behavior. Therapeutic strategies aimed at enhancing tumor-suppressive functions of SASP while minimizing tumor-promoting effects could significantly improve cancer treatment efficacy [7, 1, 15, 23, 26]. Understanding specific SASP profiles associated with different senescence-inducing agents will guide precise therapeutic interventions.

3.3 Cellular Stress Responses and Bioenergetics

Cellular stress responses and bioenergetics are critical in inducing senescence, determining cellular fate under stress. Senescence is often triggered by stressors like DNA damage and oxidative stress, activating pathways that lead to growth arrest. The DNA damage response (DDR) is a key mediator, detecting and repairing DNA lesions, while triggering senescence when damage is irreparable [2]. This response is linked to bioenergetic changes, as energy metabolism is reprogrammed to support the senescent phenotype.

Mitochondrial dysfunction, a hallmark of senescent cells, contributes to altered bioenergetics and increased reactive oxygen species (ROS) production, exacerbating DNA damage and reinforcing senescence [1]. The metabolic shift in senescent cells, characterized by changes in glycolysis and mitochondrial activity, underscores bioenergetics' role in maintaining senescence. The AMP-activated protein kinase (AMPK) pathway, a central regulator of energy homeostasis, is activated in response to metabolic stress and implicated in senescence regulation. AMPK activation maintains energy balance and modulates the senescence-associated secretory phenotype (SASP), influencing senescence's impact on the tumor microenvironment [5]. Targeting bioenergetic pathways may offer therapeutic potential for modulating senescence and its effects on cancer progression.

3.4 Dual Nature and Paradox of Senescence

The dual nature of senescence in cancer biology is characterized by its ability to both suppress and promote tumor progression, complicating therapeutic strategies. Oncogene-induced senescence (OIS), traditionally viewed as tumor-suppressive, can paradoxically facilitate tumorigenesis under specific conditions, such as TP53 mutations, which can shift OIS's role from prevention to promotion of tumor formation [27]. These mutations illustrate how senescence can contribute to tumor progression when regulatory pathways are altered.

Senescent cells have multifaceted effects, including influencing tumor growth, angiogenesis, cellular reprogramming, and immune interactions [24]. The secretory phenotype (SASP) can enhance tumor suppression by promoting immune clearance while fostering a tumor-promoting microenvironment through pro-inflammatory signals [1]. The theoretical perspective that senescence, traditionally considered irreversible, can be reversed under certain stress conditions complicates its role in cancer biology, potentially leading to aggressive tumor phenotypes [22]. Interactions between chromatin and the nuclear lamina are crucial in regulating nuclear organization, potentially contributing to senescence's paradoxical effects on tumor progression [28].

In cancer therapy, the dual nature of senescence is further illustrated by autophagy's role in mesenchymal stem cells (MSCs), which can act as both pro-senescence and anti-senescence mechanisms depending on the cellular context [13]. Targeting pathways like LPAR1 disrupts critical processes such as FLNA phosphorylation, showcasing senescence's paradoxical effects on cancer progression [29]. The dual nature of senescence poses significant challenges in cancer treatment, as it can protect against cancer while also contributing to tumor progression and relapse, particularly in aging and therapeutic contexts [19]. Understanding these paradoxical effects is essential for developing therapeutic strategies that effectively exploit senescence pathways to improve cancer treatment outcomes.

4 Senescence-Inducing Agents

4.1 Chemical and Pharmacological Senescence-Inducing Agents

Method Name	Mechanism of Action	Therapeutic Applications	Combination Strategies
Baicalin[9]	Depp Upregulation	Colon Cancer Treatment	Baicalin With Therapies
STM[12]	Dna Damage Induction	Treating Various Cancers	With Other Treatments

Table 1: Overview of senescence-inducing agents, their mechanisms of action, therapeutic applications, and potential combination strategies in cancer treatment. The table highlights the roles of Baicalin and STM in cancer therapy, emphasizing their mechanisms and synergistic potential with other treatments.

Chemical and pharmacological agents that induce senescence in cancer cells are pivotal in inhibiting proliferation and enhancing therapeutic efficacy by targeting specific molecular pathways. QC6352,

a selective KDM4C inhibitor, exemplifies this by inducing senescence in gastric cancer cells through histone methylation alterations, emphasizing the role of epigenetic modulators in cancer therapy [30]. Chemotherapeutics like doxorubicin, irinotecan, and methotrexate are effective across various cancers by inducing DNA damage and stress responses [31]. Natural compounds, such as baicalin, also show promise in inducing senescence, particularly in colon cancer, highlighting their therapeutic potential [9].

Table 1 provides a comprehensive summary of chemical and pharmacological agents that induce senescence in cancer cells, detailing their mechanisms, therapeutic applications, and combination strategies, as discussed in the preceding section. Targeting signaling pathways, such as LPAR1, facilitates senescence induction, as seen with agents affecting FLNA phosphorylation and MRTF-A activity in hepatocellular carcinoma cells [29]. Combining senescence inducers with senolytics, which eliminate senescent cells, offers a promising strategy to enhance treatment efficacy and reduce adverse effects from senescent cell accumulation [32]. The SenTraGor compound advances senescent cell detection while preserving RNA stability, aiding the application of senescence-inducing agents [12].

These agents are crucial in cancer therapy by targeting pathways leading to permanent cell cycle arrest, especially in cancer cells resistant to apoptosis due to apoptotic signaling pathway mutations. Chemotherapy and immunotherapy often trigger senescence, contributing to tumor regression and inhibiting further proliferation. The senescence-associated secretory phenotype (SASP) also influences the tumor microenvironment, affecting cancer progression. Understanding therapy-induced senescence mechanisms is essential for optimizing cancer treatments [7, 31, 33, 8, 11].

4.2 Epigenetic and Genetic Modulators

Epigenetic and genetic modulators are critical in inducing senescence in cancer cells by altering gene expression and chromatin structure, thereby influencing cellular aging and tumor suppression. Targeting the distal TERT promoter and silencing DNMT3B in glioma cells exemplifies the therapeutic potential of epigenetic regulation in telomerase activity, a key factor in cellular immortality and tumor progression [14]. Changes in histone modifications and DNA methylation are vital for establishing and maintaining the senescent phenotype, as seen in aging models [4, 16, 12, 28]. HDAC inhibitors induce senescence by altering chromatin accessibility and promoting senescence-associated gene expression, activating tumor suppressor pathways and enforcing stable growth arrest.

Genetic modulators, including tumor suppressor genes such as p53 and Rb, further illustrate senescence regulation complexity. Oncogene-induced senescence (OIS) acts as a barrier to tumorigenesis by inducing permanent cell cycle arrest and promoting cell cycle inhibitor upregulation, limiting uncontrolled proliferation. However, OIS can also contribute to tumor development through pro-tumorigenic factors secreted by senescent cells, reflecting its dual role in cancer biology [34, 35, 36, 17, 37]. The balance between oncogene activation and tumor suppressor function is crucial in determining the senescence response, presenting opportunities for targeted interventions exploiting these genetic interactions.

Advancements in genetic modulation techniques, particularly CRISPR/Cas9-mediated gene editing, hold significant potential to enhance the specificity and effectiveness of inducing cellular senescence in cancer cells. This approach aims to optimize therapeutic strategies by leveraging senescence's dual nature, acting as both a protective mechanism against tumor progression and a contributor to inflammation and pathology when dysregulated. By targeting specific genetic pathways, researchers aim to enhance senescence induction in response to various cancer treatments, contributing to tumor regression and improved outcomes [4, 12, 8]. These advancements provide a framework for developing personalized therapeutic strategies that leverage the unique genetic and epigenetic landscapes of individual tumors.

4.3 Targeted Therapies and Signaling Pathway Modulation

Targeted therapies and signaling pathway modulation offer sophisticated approaches in inducing senescence, enhancing cancer treatment efficacy by disrupting molecular pathways critical for tumor cell survival and proliferation. This induces a permanent halt in the cell cycle, promoting tumor growth cessation and enhancing immune clearance of senescent cells, contributing to tumor regression. Therapy-induced senescence (TIS) is a significant mechanism of action for various cancer

treatments, including chemotherapy and targeted therapies, offering a promising avenue for treatment improvement [5, 22, 3, 1, 8].

The 'one-two punch' therapy exemplifies the potential of combining targeted agents to enhance senescence induction. For instance, combining QC6352, a selective KDM4C inhibitor, with SSK1 enforces senescence by targeting the epigenetic landscape and chromatin organization [30]. Baicalin, a natural compound, also exemplifies targeted therapy through its modulation of signaling pathways to induce senescence, altering key cascades and elucidating its mechanism of action [9].

Targeting pathways such as LPAR1, affecting FLNA phosphorylation and MRTF-A activity, illustrates the complexity of targeted interventions in inducing senescence. By disrupting specific oncogenic pathways, targeted therapies induce cellular senescence, leading to permanent cell cycle arrest and enhanced immune clearance. This strategy not only halts cancer cell proliferation but also leverages the senescence response to mitigate tumor relapse and metastasis risks, improving treatment outcomes [22, 3, 8].

Targeted therapies and signaling pathway modulation are integral to developing effective senescence-inducing strategies. By precisely targeting molecular pathways involving oncogenes like MYC and RAS and harnessing the synergistic effects of combined therapies, including pro-senescence strategies and natural polyphenols, these innovative approaches show substantial potential for enhancing cancer treatment outcomes and overcoming resistance mechanisms associated with traditional therapies [3, 38, 5]. As research progresses, refining and integrating these strategies into clinical practice will be crucial for optimizing the therapeutic potential of senescence pathways.

4.4 Senescence-Associated Secretory Phenotype (SASP) Modulation

Modulating the senescence-associated secretory phenotype (SASP) is vital for enhancing the efficacy of senescence-inducing agents in cancer treatment. SASPs significantly influence tumor progression by altering the tumor microenvironment through the secretion of various factors, including chemokines, growth factors, and cytokines. The dual role of SASPs, which can promote or inhibit tumor growth, underscores the importance of interventions aimed at clearing senescent cells or mitigating adverse SASP effects to optimize cancer therapies [7, 1]. SASP's complex mixture of cytokines, chemokines, growth factors, and proteases necessitates precise modulation to maximize therapeutic benefits while minimizing adverse effects.

A primary challenge in SASP modulation is its role in promoting tumor-like cell mass formation, particularly with TP53 mutations, which enable oncogenic cell survival by leveraging SASP factors. Understanding TP53 mutations' influence on SASP informs therapies that mitigate the tumor-promoting aspects of SASP [27]. Strategies to modulate SASP involve targeting key regulatory pathways and transcription factors governing its expression. Inhibiting signaling pathways driving pro-inflammatory and pro-tumorigenic SASP aspects can shift the tumor microenvironment to a more tumor-suppressive phenotype, crucial for aggressive cancer subtypes where conventional therapies are limited [1, 26].

The interplay between SASPs and the immune system creates a complex landscape for therapeutic intervention, as SASPs can promote tumor progression or enhance immune surveillance, highlighting the dual role of cellular senescence in cancer dynamics and treatment strategies [4, 7, 1, 21]. Enhancing immune-mediated clearance of senescent cells through SASP modulation can improve senescence-inducing therapies' efficacy, potentially utilizing immune checkpoint inhibitors or other immunomodulatory agents to bolster the immune response against senescent cells.

SASP modulation is a multifaceted component in refining senescence-based cancer therapies, influencing tumor biology by inhibiting and promoting cancer progression, thereby affecting the tumor microenvironment and therapeutic outcomes [4, 7, 1, 26]. By strategically targeting SASP-regulating pathways and factors, it is possible to enhance senescence-inducing agents' therapeutic efficacy and improve patient outcomes. Continued research into SASP intricacies will be essential for developing targeted modulation strategies to maximize senescence benefits in cancer treatment.

5 Challenges and Limitations

Understanding the complexities of cancer therapy involves recognizing the challenges and limitations that influence treatment efficacy and patient outcomes. This section delves into the intricate dynamics of senescence mechanisms, which serve as both a protective response against tumorigenesis and a potential barrier to effective cancer treatment, highlighting the need for innovative strategies that leverage the benefits of senescence while mitigating its drawbacks.

5.1 Complexity of Senescence Mechanisms

The complexity of senescence mechanisms in cancer therapy arises from the interplay of biological pathways and context-dependent effects, presenting significant challenges for therapeutic strategies. Senescence, governed by a multifaceted network of pathways, exhibits both beneficial and detrimental roles in cancer progression, necessitating a nuanced understanding of these processes [1, 5]. Inducing senescence in non-tumor cells during cancer therapy can result in inflammation, secondary tumors, and relapse [10], emphasizing the need for selective targeting strategies. The interactions between genetic mutations and epigenetic regulation further complicate therapeutic approaches, as these interactions remain inadequately understood [37]. Epigenetic regulation of the TERT promoter exemplifies the challenges in identifying specific methylation sites that influence gene expression [14]. Oncogene-induced senescence (OIS) serves as a defense mechanism against cancer; however, the heterogeneity of cellular responses complicates the understanding of how senescence affects tumor dynamics [18]. The lack of specific markers for identifying senescent tumor cells (STCs) poses another challenge, as current studies require larger cohorts for validation [1]. Existing methods, such as the senescence-associated -galactosidase assay, compromise RNA stability and present challenges for effective senescence therapy [12]. Targeting specific transcriptional activities, including COX-2 and p53 interactions, further complicates therapeutic strategies [18]. Understanding the dual effects of senescence on physiological and pathological processes, including cancer and aging, is crucial for developing targeted therapies that modulate senescence for improved outcomes [4, 16, 2, 39].

5.2 Heterogeneity and Variability

The heterogeneity and variability of senescence responses among different cancer types and patients present significant challenges for the effective implementation of pro-senescence therapies. This variability is influenced by numerous factors, including genetic mutations, tissue specificity, and differential expression of senescence markers, complicating the characterization and targeting of senescent cells. In gastric cancer, varying TP53 mutation statuses contribute to the heterogeneity of senescence responses, posing challenges in designing uniform therapeutic strategies [30]. Variability in response to pro-senescence therapy is exemplified in melanoma, where distinct cell lines exhibit different treatment responses, potentially leading to unintended consequences such as promoting inflammation and tumor progression [3]. The senescence-associated secretory phenotype (SASP) adds complexity due to its context-dependent effects, which can either suppress or promote tumor growth and therapy resistance. Current studies often overlook the adverse effects of SASP, indicating a gap in understanding the long-term implications of therapy-induced senescence (TIS) [40]. The potential variability in response among different cancer cell types, as observed with agents like baicalin, underscores the challenges in achieving consistent therapeutic efficacy [9]. Addressing these challenges requires a comprehensive understanding of factors contributing to senescence variability and the development of tailored therapeutic strategies that account for individual tumor characteristics [7, 21, 31, 22, 4].

5.3 Resistance and Selectivity Issues

Resistance and selectivity issues in targeting senescent cells present significant challenges in applying pro-senescence therapies. A primary concern is effectively targeting and eliminating oncogene-induced senescent cells to prevent their potential malignant transformation while preserving beneficial aspects of senescence [41]. In hepatocellular carcinoma (HCC), the ineffectiveness of existing methods to remove chemotherapy-induced senescent cells underscores a critical treatment challenge [42]. The selectivity of senescence-inducing agents is complicated by the heterogeneity of senescent cell populations across different tumor types and within the tumor microenvironment. Emerging resistance mechanisms, particularly alterations in senescence-associated signaling pathways, present

significant challenges to the sustained efficacy of pro-senescence therapies, which are increasingly recognized for their dual role in promoting beneficial outcomes and potentially contributing to pathological conditions when dysregulated. Addressing resistance and selectivity issues requires developing novel therapeutic strategies that selectively target senescent cells while overcoming resistance mechanisms. This involves identifying specific biomarkers for senescence, refining senolytic agents, and integrating combination therapies to enhance treatment outcomes [4, 43, 39, 33].

5.4 Biomarker Identification and Validation

Benchmark	Size	Domain	Task Format	Metric
TIS-BM[31]	5,000	Cancer Biology	Senescence Assessment	SA-galactosidase Activity, Granularity

Table 2: Table detailing the TIS-BM benchmark used for assessing senescence in cancer biology, including its size, domain, task format, and evaluation metrics. This benchmark is crucial for understanding the senescence-associated features in tumor biology and validating potential biomarkers for clinical applications.

The identification and validation of biomarkers for senescence in cancer treatment present significant challenges due to the complexity and heterogeneity of senescent tumor cells (STCs). Table 2 provides a detailed overview of the TIS-BM benchmark, which is instrumental in the identification and validation of biomarkers for senescence in cancer treatment. A major obstacle is the lack of specific and universal markers that can reliably distinguish senescent cells from non-senescent ones across various cancer types. Key gaps in understanding include unanswered questions regarding the precise mechanisms by which STCs influence tumor behavior [23]. The variability in senescence-associated secretory phenotype (SASP) profiles further complicates the identification of reliable biomarkers, as SASP components can exert both tumor-suppressive and tumor-promoting effects. Moreover, validating potential biomarkers is hindered by the need for robust and reproducible assays that accurately detect senescence in clinical samples. The integration of multi-omics approaches, including genomics, transcriptomics, and proteomics, holds promise for advancing biomarker discovery by providing a holistic view of the molecular changes associated with senescence. These approaches can enhance the discovery of novel biomarkers that provide insights into the intricate regulatory networks governing cellular senescence, which plays a dual role in suppressing and promoting tumor progression [4, 16, 12, 21]. Overcoming the challenges in biomarker identification and validation is crucial for successfully implementing pro-senescence therapies in cancer treatment [5, 12, 4, 39, 2].

5.5 Adverse Effects and Therapeutic Challenges

Implementing pro-senescence therapy in cancer treatment is accompanied by several adverse effects and therapeutic challenges that necessitate careful consideration. One primary concern is the potential for therapy-induced senescence (TIS) to contribute to tumor progression rather than suppression. This paradox arises from the senescence-associated secretory phenotype (SASP), which can promote inflammation, angiogenesis, and tissue remodeling, thereby fostering a tumor-permissive environment. Another significant challenge is the risk of inducing senescence in non-tumor cells, which can lead to adverse effects such as chronic inflammation and tissue dysfunction [10]. The heterogeneity of senescence responses across different cancer types and individual patients further complicates implementing pro-senescence therapies. Moreover, the emergence of resistance mechanisms, such as alterations in senescence-associated signaling pathways, can undermine the effectiveness of pro-senescence therapies. Addressing these resistance issues requires developing combination therapies that integrate senolytics and other targeted agents to enhance the durability of treatment responses [41].

6 Current Research and Developments

The rapidly evolving field of senescence therapy is marked by innovative strategies and significant advancements that enhance our understanding of cellular senescence in cancer treatment. This section highlights recent developments in senescence-inducing agents, which show promise in improving therapeutic outcomes against aggressive cancer subtypes.

6.1 Advancements in Senescence-Inducing Agents

Recent progress in senescence-inducing agents has expanded therapeutic options for aggressive cancers. Ribosomal proteins have emerged as promising targets, demonstrating potential to enforce senescence and inhibit tumor proliferation [26]. Polyphenols, notably baicalin, have been recognized for inducing senescence in cancer prevention and therapy, highlighting their clinical potential [38, 9]. Targeting LPAR1 in hepatocellular carcinoma offers new avenues for modulating senescence [29], while COX-2-p53 interactions underscore the importance of molecular interactions in agent design [18]. Senescence inducers like doxorubicin activate specific markers, suggesting pathway-specific interventions to enhance efficacy [44]. Understanding roles of cellular senescence (CS) and senescence-associated secretory phenotypes (SASPs) in tumor biology reveals new therapeutic targets [1]. Future research should focus on developing pathway-specific senolytic compounds, integrating senescence-inducing agents into comprehensive regimens to improve outcomes and counteract resistance [40].

6.2 Molecular Pathways and Mechanisms

Recent insights into molecular pathways and mechanisms have deepened understanding of senescence in cancer therapy. Gene expression and chromatin positioning at the nuclear lamina in senescent cells suggest targeting chromatin organization for novel strategies [45]. Intercellular communication and senescence propagation highlight complex tumor microenvironment interactions [27]. Mutations like BRAF V600E and p16INK4a overexpression in tumors offer insights into oncogene-induced senescence (OIS) and potential targeted interventions [46]. OIS mechanisms vary across cell types, necessitating tailored strategies [34]. NORE1A, p53, and Rb interactions are critical in promoting OIS, with NORE1A loss allowing oncogenic Ras to bypass senescence [36]. Signaling pathways associated with OIS provide insights into tumor progression and therapeutic potential [37]. Cellular senescence's dual role—characterized by cell cycle arrest and a distinct secretome—presents both opportunities and challenges, as modulating senescent cells may enhance treatment efficacy while addressing adverse effects [5, 7, 8, 4, 39].

6.3 Therapeutic Strategies and Senolytics

Integrating senolytics with pro-senescence therapy offers a promising cancer treatment approach. Senolytic agents selectively induce apoptosis in senescent cells, potentially enhancing pro-senescence therapy efficacy by mitigating adverse effects of senescent cell accumulation [39]. Targeting SASP can reduce inflammation and foster a tumor-suppressive microenvironment, improving outcomes [47]. Senolytic therapy shows promise in specific contexts, like reducing cervical cancer risk in HPV-infected individuals by eliminating senescent cells contributing to tumorigenesis [41]. The interplay between autophagy and mesenchymal stem cell (MSC) senescence complicates the landscape, as autophagy regulates both senescence and cellular function [13]. Understanding this relationship is crucial for enhancing MSC function in regenerative medicine and cancer therapy. In glioma treatment, DNMT3B silencing induces senescence, suggesting novel avenues with senolytics to improve efficacy [14]. Integrating senolytics into therapies advances pro-senescence therapy by selectively eliminating oncogene-induced senescent cells, enhancing cancer treatment effectiveness and addressing challenges of conventional therapies [3, 33, 4, 32, 41]. By targeting senescent cells and modulating SASP, these strategies amplify tumor-suppressive effects while mitigating drawbacks.

6.4 Challenges in Senescence Therapy

Senescence therapy faces multiple challenges essential for optimizing therapeutic potential in cancer treatment. A primary challenge is developing senolytic therapies and SASP modulators to target senescent cells and their secretory profiles [24]. SASP's complexity and dual role in tumor suppression and promotion necessitate refining strategies for enhanced specificity and efficacy [19]. Emerging trends highlight the need for research on senolytic agents and microenvironmental factors influencing senescence and tumor progression [35]. The interplay between senescent cells and the tumor microenvironment is critical, impacting senescence-based therapy efficacy. Long-term effects of targeting senescent cells in cancer patients require exploration to avoid adverse outcomes [19]. Refining detection methods and exploring additional markers enhance senescence identification in various tissues [17]. Current methods' specificity and sensitivity in heterogeneous populations remain

concerns, as accurate detection is crucial for targeting senescent cells [12]. Studying senescence in non-parenchymal liver cells and exploring therapeutic strategies targeting senescence in these cells are important research areas [44]. Understanding senescence's implications in different contexts is essential for comprehensive approaches. Potential for senolytic therapies like D + Q to promote tumor growth rather than enhance chemotherapy efficacy underscores caution in application [42]. Addressing these challenges requires a multifaceted approach incorporating additional biological factors and testing across diverse organisms and conditions [48].

7 Therapeutic Strategies and Applications

7.1 Clinical Applications and Trials

The incorporation of pro-senescence therapy into cancer treatment is advancing through novel agents targeting resistant cancer subtypes. Clinical trials, such as those investigating the combination of QC6352 and SSK1 for gastric cancer with TP53 mutations, aim to exploit genetic vulnerabilities to enhance therapeutic outcomes [30]. Similarly, targeting ribosomal proteins in p16-positive basal-like breast cancer presents a new therapeutic angle for improving patient outcomes in this aggressive subtype [26]. These trials demonstrate efforts to refine pro-senescence therapy by focusing on specific molecular pathways and cancer characteristics to enhance efficacy. Understanding the dual roles of cellular senescence in cancer progression and inflammation is crucial for developing effective therapies [4, 6].

7.2 Cancer-Specific Applications

Pro-senescence therapy shows promise in addressing treatment-resistant cancers. In hepatocellular carcinoma (HCC), targeting LPAR1 signaling is a promising strategy for inducing senescence and halting tumor progression [29]. For gastric cancer, the QC6352 and SSK1 combination aims to enhance senescence induction in tumors with TP53 mutations, potentially overcoming resistance and improving treatment efficacy [30]. In melanoma, modulating signaling pathways and using natural compounds like baicalin can induce senescence and inhibit tumor growth [9]. In papillary thyroid carcinoma, targeting senescent tumor cells (STCs) may reduce collective invasion and metastasis, offering hope for treatment-resistant malignancies [10]. Pro-senescence therapy, by inducing irreversible cell cycle arrest, not only inhibits cancer cell replication but also promotes a favorable immune response, addressing malignancy and associated inflammation [4, 6].

7.3 Targeting the Tumor Microenvironment

The tumor microenvironment (TME) is crucial in cancer progression and therapy resistance, making it a target for pro-senescence therapy. Modulating the TME can enhance the efficacy of senescence-inducing agents by altering the supportive niche tumors exploit. Targeting the senescence-associated secretory phenotype (SASP) can shift the TME to a tumor-suppressive state, improving therapeutic potential [1]. Senolytic agents can selectively eliminate senescent cells, reducing SASP effects on the TME [41]. Modulating pathways like LPAR1 disrupts supportive interactions in HCC [29]. The interplay between senescent and immune cells within the TME is vital for targeting the tumor microenvironment. Enhancing immune cell recruitment and activation can improve senescent cell elimination and bolster tumor-suppressive effects [21, 8, 4, 23, 41]. Combining pro-senescence therapies with immune checkpoint inhibitors can enhance the anti-tumor immune response and improve outcomes.

7.4 Innovative Therapeutic Approaches

Innovative approaches integrating pro-senescence therapy with other modalities are promising for enhancing cancer treatment efficacy. Combining senescence-inducing agents with therapies targeting pathways in senescence revertants can mitigate their effects and improve outcomes [22]. Integrating pro-senescence therapy with immunotherapy offers a novel approach to enhance the anti-tumor immune response. Senescent cells, with altered antigen presentation, influence the immune landscape. Combining senescence-inducing agents with immune checkpoint inhibitors can potentiate senescent cell clearance and enhance treatment efficacy [4, 39, 21]. Combination therapies targeting metabolic

vulnerabilities in senescent cells can induce apoptosis, promoting elimination while preserving healthy tissues [3, 8, 33, 4, 41]. These strategies enhance the therapeutic index of pro-senescence therapies and reduce adverse effects. By addressing senescence reversal, immune modulation, and metabolic vulnerabilities, these approaches aim to enhance the efficacy of senescence pathways, achieving more effective responses in cancer patients. Integrating immune dynamics and identifying metabolic weaknesses are critical for innovative treatments leveraging senescence's beneficial aspects while mitigating drawbacks [5, 21, 8, 4, 39].

8 Conclusion

8.1 Challenges and Future Directions

Pro-senescence therapy's potential in cancer treatment is accompanied by significant challenges that necessitate deeper investigation to optimize its efficacy. A critical issue is the complex role of the senescence-associated secretory phenotype (SASP), which can either suppress or promote tumor growth. Advancing this therapeutic approach requires the development of senolytic and senomorphic therapies that can selectively mitigate the detrimental effects of SASPs while preserving their tumor-suppressive properties. This effort must be supported by a comprehensive understanding of senescence-immune system interactions and the identification of reliable biomarkers for assessing therapeutic outcomes.

The refinement of treatment protocols for emerging senescence-inducing agents, such as QC6352 and SSK1, is another important research focus. It is crucial to evaluate these agents' long-term safety and clinical effectiveness to ensure their successful integration into cancer treatment regimens. Personalized medicine approaches, particularly those examining the impact of epigenetic modifications on senescence pathways, hold promise for enhancing the precision and effectiveness of pro-senescence therapies.

A thorough exploration of the molecular dynamics between senescent cells and their surrounding microenvironment is essential for developing strategies to eliminate harmful senescent cells. This includes pinpointing proteins that regulate senescence and devising therapies targeting their negative regulators. Expanding the applicability of techniques like SenTraGor across different cancer types and clarifying the pathways connecting senescence and tumor progression are crucial steps forward.

Integrating pro-senescence therapy with other treatment modalities, such as immunotherapies, could amplify the anti-tumor immune response and improve patient outcomes. Further investigation into the molecular targets involved in various forms of cellular senescence and their interactions may reveal additional therapeutic opportunities.

Addressing these challenges and exploring these future directions are vital for advancing pro-senescence therapy and realizing its full potential to enhance cancer treatment outcomes. Continued research into the specific pathways governing autophagy and their context-dependent roles will be instrumental in refining therapeutic strategies.

References

[1] Zening Dong, Yahan Luo, Zhangchen Yuan, Yu Tian, Tianqiang Jin, and Feng Xu. Cellular senescence and sasp in tumor progression and therapeutic opportunities. *Molecular Cancer*, 23(1):181, 2024.

[2] Nicolás Herranz, Jesús Gil, et al. Mechanisms and functions of cellular senescence. *The Journal of clinical investigation*, 128(4):1238–1246, 2018.

[3] Fan Zhang. *Pro-senescence therapy by targeting MYC and its network as a strategy to combat cancer*. PhD thesis, Karolinska Institutet (Sweden), 2019.

[4] Camilla SA Davan-Wetton, Emanuela Pessolano, Mauro Perretti, and Trinidad Montero-Melendez. Senescence under appraisal: hopes and challenges revisited. *Cellular and Molecular Life Sciences*, 78(7):3333–3354, 2021.

[5] Seongju Lee and Jae-Seon Lee. Cellular senescence: a promising strategy for cancer therapy. *BMB reports*, 52(1):35, 2019.

[6] Arianna Calcinotto and Andrea Alimonti. Aging tumour cells to cure cancer:"pro-senescence" therapy for cancer. *Swiss Medical Weekly*, 147(0304):w14367–w14367, 2017.

[7] Maria Patrizia Mongiardi, Manuela Pellegrini, Roberto Pallini, Andrea Levi, and Maria Laura Falchetti. Cancer response to therapy-induced senescence: A matter of dose and timing. *Cancers*, 13(3):484, 2021.

[8] Shenghui Qin, Bradley A Schulte, and Gavin Y Wang. Role of senescence induction in cancer treatment. *World journal of clinical oncology*, 9(8):180, 2018.

[9] Zhou Wang, Lingman Ma, Mengqi Su, Yiran Zhou, Ke Mao, Chengqin Li, Guangyong Peng, Changlin Zhou, Baiyong Shen, and Jie Dou. Baicalin induces cellular senescence in human colon cancer cells via upregulation of depp and the activation of ras/raf/mek/erk signaling. *Cell death & disease*, 9(2):217, 2018.

[10] Young Hwa Kim, Yong Won Choi, Jeonghun Lee, Euy Young Soh, Jang-Hee Kim, and Tae Jun Park. Senescent tumor cells lead the collective invasion in thyroid cancer. *Nature communications*, 8(1):15208, 2017.

[11] Justyna Mikuła-Pietrasik, Arkadiusz Niklas, Paweł Uruski, Andrzej Tykarski, and Krzysztof Książek. Mechanisms and significance of therapy-induced and spontaneous senescence of cancer cells. *Cellular and Molecular Life Sciences*, 77:213–229, 2020.

[12] Eirini-Stavroula Komseli, Ioannis S Pateras, Thorbjørn Krejsgaard, Konrad Stawiski, Sophia V Rizou, Alexander Polyzos, Fani-Marlen Roumelioti, Maria Chiourea, Ioanna Mourkioti, Eleni Paparouna, et al. A prototypical non-malignant epithelial model to study genome dynamics and concurrently monitor micro-rnas and proteins in situ during oncogene-induced senescence. *BMC genomics*, 19:1–22, 2018.

[13] Raffaella Rastaldo, Emanuela Vitale, and Claudia Giachino. Dual role of autophagy in regulation of mesenchymal stem cell senescence. *Frontiers in Cell and Developmental Biology*, 8:276, 2020.

[14] Naz Şerifoğlu, Begün Erbaba, Michelle M Adams, and Ayça Arslan-Ergül. Tert distal promoter gc islands are critical for telomerase and together with dnmt3b silencing may serve as a senescence-inducing agent in gliomas. *Journal of Neurogenetics*, 36(4):89–97, 2022.

[15] Dilara Demirci, Bengisu Dayanc, Fatma Aybuke Mazi, and Serif Senturk. The jekyll and hyde of cellular senescence in cancer. *Cells*, 10(2):208, 2021.

[16] Corinne Sidler, Olga Kovalchuk, and Igor Kovalchuk. Epigenetic regulation of cellular senescence and aging. *Frontiers in genetics*, 8:138, 2017.

[17] Kwan-Hyuck Baek and Sandra Ryeom. Detection of oncogene-induced senescence in vivo. *Oncogene-Induced Senescence: Methods and Protocols*, pages 185–198, 2017.

[18] Hyeon Ju Lee, So Ra Kim, Yu-Jin Jung, and Jeong A Han. Cyclooxygenase-2 induces neoplastic transformation by inhibiting p53-dependent oncogene-induced senescence. *Scientific Reports*, 11(1):9853, 2021.

[19] Markus Schosserer, Johannes Grillari, and Michael Breitenbach. The dual role of cellular senescence in developing tumors and their response to cancer therapy. *Frontiers in oncology*, 7:278, 2017.

[20] Jing Yang, Mengmeng Liu, Dongchun Hong, Musheng Zeng, and Xing Zhang. The paradoxical role of cellular senescence in cancer. *Frontiers in cell and developmental biology*, 9:722205, 2021.

[21] Luis I Prieto and Darren J Baker. Cellular senescence and the immune system in cancer. *Gerontology*, 65(5):505–512, 2019.

[22] Leixiang Yang, Jia Fang, and Jiandong Chen. Tumor cell senescence response produces aggressive variants. *Cell Death Discovery*, 3(1):1–11, 2017.

[23] Soon Sang Park, Yong Won Choi, Jang-Hee Kim, Hong Seok Kim, and Tae Jun Park. Senescent tumor cells: an overlooked adversary in the battle against cancer. *Experimental & molecular medicine*, 53(12):1834–1841, 2021.

[24] Jose Mario Gonzalez-Meljem, John Richard Apps, Helen Christina Fraser, and Juan Pedro Martinez-Barbera. Paracrine roles of cellular senescence in promoting tumourigenesis. *British journal of cancer*, 118(10):1283–1288, 2018.

[25] Dan Wu, Hua Tan, Weijun Su, Dongmei Cheng, Guanwen Wang, Juan Wang, Ding A Ma, George M Dong, and Peiqing Sun. Mzf1 mediates oncogene-induced senescence by promoting the transcription of p16ink4a. *Oncogene*, 41(3):414–426, 2022.

[26] Madeleine Moore, Luke Gammon, Sally Dreger, James Koh, James C Garbe, Martha R Stampfer, Michael Philpott, Louise Jones, and Cleo L Bishop. Ribosomal stress-induced senescence as a novel pro-senescence strategy for p16 positive basal-like breast cancer. *bioRxiv*, page 469445, 2018.

[27] Yukinari Haraoka, Yuki Akieda, Yuri Nagai, Chihiro Mogi, and Tohru Ishitani. Zebrafish imaging reveals tp53 mutation switching oncogene-induced senescence from suppressor to driver in primary tumorigenesis. *Nature Communications*, 13(1):1417, 2022.

[28] Michael Chiang, Davide Michieletto, Chris A. Brackley, Nattaphon Rattanavirotkul, Hisham Mohammed, Davide Marenduzzo, and Tamir Chandra. Polymer modelling predicts chromosome reorganisation in senescence, 2020.

[29] Andreas Konopa, Melanie A Meier, Miriam J Franz, Emanuele Bernardinelli, Anna-Lena Voegele, Raja Atreya, Silvia Ribback, Stephanie Roessler, Achim Aigner, Kerstin Singer, et al. Lpa receptor 1 (lpar1) is a novel interaction partner of filamin a that promotes filamin a phosphorylation, mrtf-a transcriptional activity and oncogene-induced senescence. *Oncogenesis*, 11(1):69, 2022.

[30] Kaiqing Wang, Zhicheng Gong, Yanyan Chen, Meimei Zhang, Suzeng Wang, Surui Yao, Zhihui Liu, Zhaohui Huang, and Bojian Fei. Kdm4c-mediated senescence defense is a targetable vulnerability in gastric cancer harboring tp53 mutations. *Clinical epigenetics*, 15(1):163, 2023.

[31] Agnieszka Bojko, Joanna Czarnecka-Herok, Agata Charzynska, Michal Dabrowski, and Ewa Sikora. Diversity of the senescence phenotype of cancer cells treated with chemotherapeutic agents. *Cells*, 8(12):1501, 2019.

[32] Shuaishuai Ni, Qian Liu, Xin Chen, Lele Ding, Lili Cai, Fei Mao, Donglei Shi, Robert M Hoffman, Jian Li, and Lijun Jia. Pro-senescence neddylation inhibitor combined with a senescence activated β-galactosidase prodrug to selectively target cancer cells. *Signal Transduction and Targeted Therapy*, 7(1):313, 2022.

[33] Natalie Kudlova, Juan Bautista De Sanctis, and Marian Hajduch. Cellular senescence: molecular targets, biomarkers, and senolytic drugs. *International Journal of Molecular Sciences*, 23(8):4168, 2022.

[34] Marcos Seoane, Jose A Costoya, and Victor M Arce. Uncoupling oncogene-induced senescence (ois) and dna damage response (ddr) triggered by dna hyper-replication: lessons from primary mouse embryo astrocytes (mea). *Scientific reports*, 7(1):12991, 2017.

[35] Lorenzo Galluzzi and Ilio Vitale. Oncogene-induced senescence and tumour control in complex biological systems. *Cell Death & Differentiation*, 25(6):1005–1006, 2018.

[36] Thibaut Barnoud, M Lee Schmidt, Howard Donninger, and Geoffrey J Clark. The role of the nore1a tumor suppressor in oncogene-induced senescence. *Cancer letters*, 400:30–36, 2017.

[37] Xue-ling Liu, Jian Ding, and Ling-hua Meng. Oncogene-induced senescence: a double edged sword in cancer. *Acta Pharmacologica Sinica*, 39(10):1553–1558, 2018.

[38] Yan Bian, Juntong Wei, Changsheng Zhao, and Guorong Li. Natural polyphenols targeting senescence: A novel prevention and therapy strategy for cancer. *International journal of molecular sciences*, 21(2):684, 2020.

[39] Zehuan Liao, Han Lin Yeo, Siaw Wen Wong, and Yan Zhao. Cellular senescence: mechanisms and therapeutic potential. *Biomedicines*, 9(12):1769, 2021.

[40] Julia Kallenbach, Golnaz Atri Roozbahani, Mehdi Heidari Horestani, and Aria Baniahmad. Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer. *Cell & Bioscience*, 12(1):200, 2022.

[41] Tareq Saleh, Ashraf I Khasawneh, Nisreen Himsawi, Jumana Abu-Raideh, Vera Ejeilat, Ahmed M Elshazly, and David A Gewirtz. Senolytic therapy: A potential approach for the elimination of oncogene-induced senescent hpv-positive cells. *International Journal of Molecular Sciences*, 23(24):15512, 2022.

[42] Kristina Kovacovicova, Marianna Skolnaja, Mihkel Heinmaa, Martin Mistrik, Pille Pata, Illar Pata, Jiri Bartek, and Manlio Vinciguerra. Senolytic cocktail dasatinib+ quercetin (d+ q) does not enhance the efficacy of senescence-inducing chemotherapy in liver cancer. *Frontiers in oncology*, 8:459, 2018.

[43] Jun Guo, Xiuqing Huang, Lin Dou, Mingjing Yan, Tao Shen, Weiqing Tang, and Jian Li. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. *Signal transduction and targeted therapy*, 7(1):391, 2022.

[44] Pavitra Kumar, Mohsin Hassan, Frank Tacke, and Cornelius Engelmann. Delineating the heterogeneity of senescence-induced-functional alterations in hepatocytes. *Cellular and Molecular Life Sciences*, 81(1):200, 2024.

[45] Christelle Lenain, Carolyn A de Graaf, Ludo Pagie, Nils L Visser, Marcel de Haas, Sandra S de Vries, Daniel Peric-Hupkes, Bas van Steensel, and Daniel S Peeper. Massive reshaping of genome–nuclear lamina interactions during oncogene-induced senescence. *Genome research*, 27(10):1634–1644, 2017.

[46] Lucia Kim, Young Sam Kim, Jin Soo Lee, Suk Jin Choi, In Suh Park, Jee Young Han, Joon Mee Kim, and Young Chae Chu. Ciliated muconodular papillary tumor of the lung harboring braf v600e mutation and p16ink4a overexpression without proliferative activity may represent an example of oncogene-induced senescence. *Journal of Thoracic Disease*, 9(12):E1039, 2017.

[47] Juliane L Buhl, Florian Selt, Thomas Hielscher, Romain Guiho, Jonas Ecker, Felix Sahm, Johannes Ridinger, Dennis Riehl, Diren Usta, Britta Ismer, et al. The senescence-associated secretory phenotype mediates oncogene-induced senescence in pediatric pilocytic astrocytoma. *Clinical Cancer Research*, 25(6):1851–1866, 2019.

[48] Jean-François Delmas and Laurence Marsalle. Detection of cellular aging in a galton-watson process, 2008.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.